Clinical Trials Browser

NCT02091245 2026-05-29

Phase I Trial of the Selective Inhibitor of Nuclear Export, KPT-330, in Relapsed Childhood ALL and AML

LymphoidMyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT04898894 2026-04-28

Study of Selinexor and Venetoclax in Combination With Chemotherapy in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia

Phase 1 Active not recruiting

37 enrolled

Other hematologic neoplasm

Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute

NCT07437170 2026-02-27

Selinexor Combined With Induction Chemotherapy for Children With NUP98-positive AML

Phase 2 Active not recruiting

10 enrolled

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT07094464 2025-07-30

Maintenance Therapy With Selinexor and Azacitidine in TP53 Mutant AML/MDS After Transplantation

Phase 1 Active not recruiting

20 enrolled

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT06449482 2025-05-30

Selinexor、Venetoclax and Azactidine in the Treatment of ND AML Patients Who Are Not Eligible for Intense Chemotherapy

Phase 1/2 Terminated

6 enrolled

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT06900088 2025-03-28

Selinexor Combined With Azacitidine Therapy in High-Risk Myeloid Neoplasms Patients

Phase 2 Not yet recruiting

20 enrolled

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT06765928 2025-01-09

Selinexor Combined With Venetoclax Maintenance Therapy After Allo-HSCT

Phase 2 Not yet recruiting

73 enrolled

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT03955783 2024-10-26

Venetoclax and Selinexor in Treating Patients with Relapsed or Refractory High Risk Hematologic Malignancies

Phase 1 Completed

78 enrolled

LymphoidOther hematologic neoplasm

Lymphoma, Non-Hodgkin, Leukemia, Myeloid, Acute, Lymphoma, Large B-Cell, Diffuse

NCT05726110 2024-10-22

Selinexor in Combination With HAD or CAG Rregimens in Relapsed or Refractory Acute Myeloid Leukemia

Phase 3 Recruiting

50 enrolled

Other hematologic neoplasm

Recurrence, Leukemia, Myeloid, Acute

NCT06613035 2024-09-25

Twice-per-weekSelinexor, 2 Days Melphalan

Phase 3 Not yet recruiting

126 enrolled

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT05951855 2023-07-19

Study of Selinexor Combined With Chidamide in Relapsed/Refractory Acute Leukemia (AML) Patients

Phase 2 Unknown

42 enrolled

Other hematologic neoplasm

Recurrence, Leukemia, Myeloid, Acute

NCT02299518 2023-06-15

Selinexor and Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Phase 1 Completed

23 enrolled

Other hematologic neoplasm

Congenital Abnormalities, Leukemia, Myeloid, Acute

NCT05805072 2023-05-06

Selinexor and HAAG With/Without HMA in Relapsed/Refractory Acute Leukemia (AML) Patients

Phase NA Unknown

20 enrolled

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT05736965 2023-03-15

SAV

Phase 2 Recruiting

58 enrolled

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT02088541 2023-01-26

SOPRA

Phase 2 Completed

317 enrolled 25 charts

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT02403310 2022-10-03

A Study of Selinexor in Combination With Daunorubicin and Cytarabine for Untreated AML

Phase 1 Completed

21 enrolled

Other hematologic neoplasm

Chromosome Aberrations, Leukemia, Leukemia, Myeloid, Acute

NCT02249091 2021-08-25

A Phase II Study of Selinexor Plus Cytarabine and Idarubicin in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML)

Phase 2 Completed

42 enrolled 16 charts

Other hematologic neoplasm

Recurrence, Leukemia, Myeloid, Acute

NCT02485535 2021-05-13

Selinexor in Treating Patients With Intermediate- and High-Risk Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome After Transplant

Phase 1 Completed

12 enrolled

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT03071276 2020-05-22

Selinexor in Combination With Fludarabine and Cytarabine in Patients With Refractory or Relapsed Acute Myeloid Leukemia

Phase 2 Terminated

37 enrolled 11 charts

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT03661515 2020-05-20

FLAGINEXOR

Phase 1 Completed

16 enrolled

Other hematologic neoplasm

Recurrence, Leukemia, Myeloid, Acute

NCT02573363 2020-04-08

Selinexor With Combination Chemotherapy in Treating Patients With Acute Myeloid Leukemia

Phase 1 Completed

25 enrolled

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT02530476 2020-03-31

Phase I/II, Study of Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) + Sorafenib in Acute Myeloid Leukemia

Phase 1/2 Completed

17 enrolled 14 charts

Other hematologic neoplasm

Leukemia, Recurrence, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT02212561 2020-03-26

Selinexor With Fludarabine and Cytarabine for Treatment of Refractory or Relapsed Leukemia or Myelodysplastic Syndrome

Phase 1 Completed

19 enrolled

LymphoidMyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02416908 2020-03-13

Study of CLAG + Selinexor in Relapsed or Refractory Acute Myeloid Leukemia

Phase 1/2 Completed

40 enrolled 16 charts

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT02093403 2017-12-08

Decitabine and Selinexor in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Phase 1 Completed

25 enrolled

Other hematologic neoplasm

Congenital Abnormalities, Leukemia, Myeloid, Acute